<DOC>
	<DOCNO>NCT00190008</DOCNO>
	<brief_summary>The mechanism involve development tardive dyskinesia ( TD ) complicate . It seem several neurotransmitter system may affect , include dopaminergic , noradrenergic , gamma-amino-butyric acid ( GABA ) ergic , cholinergic peptidergic pathway . Piracetam ( 2-oxo-pyrrolidone ) nootropic drug structurally relate GABA . It use clinically treat wide range disease condition , mainly treatment organic brain syndrome , myoclonus , memory impairment , post-concussional syndrome , vertigo , alcohol withdrawal , cerebrovascular insufficiency , hypoxia , intoxication different origin mechanic brain injures . Piracetam cerebral homeostatic normalizer , neuroprotectant , cerebral metabolic enhancer brain integrative agent . It enhance brain energy , especially deficit condition : hypoxia , chemical toxicity impair cerebral microcirculation ; preserve , protect enhance synaptic membrane receptor structure plasticity . It various effect glutamate neurotransmission micromolar level piracetam potentiate potassium-induced release glutamate hippocampal nerve . It oxidant agent may useful treatment TD . Piracetam among toxicologically safe drug ever develop even mega dos . Data derive clinical report suggest piracetam improve symptom effective agent treatment different movement disorder include acute neuroleptic induce extrapyramidal symptom TD . The dos use TD treatment vary 800 mg/day 24000 mg/day . According finding symptom TD disappear period 3-7 day . To date one double-blind crossover study regard use piracetam treatment TD conduct almost 20 year ago . The finding study impressive , knowledge nobody reproduced result .</brief_summary>
	<brief_title>Piracetam Treatment Tardive Dyskinesia</brief_title>
	<detailed_description>We intend examine 40 inpatient , age 18-75 year old , suffer TD variant . Criteria inclusion study : ) DSM-IV diagnosis tardive dyskinesia ; b ) stable psychotropic regimen month prior entry study ; c ) duration TD least 1 year ; ) patient hospitalize . Exclusion criterion : ) evidence family history Huntington 's disease ; b ) evidence substance alcohol abuse ; c ) patient receive form vitamin medication ; ) patient concurrent medical illness neurological disorder may influence diagnosis tardive dyskinesia . The study design double blind , randomize crossover group study last 8 week . This period provide opportunity exclude influence spontaneous fluctuation severity TD . Full physical laboratory examination perform inpatient begin end trial . Psychotropic medication maintain fix dos throughout duration study . The capsule preparation make professional pharmacist size color capsule individual number-coded package . The capsule add patient ' usual medication give nurse . Assessments tardive dyskinesia variant do use Extrapyramidal Symptom Rating Scale ( ESRS ) baseline repeat every week , prior crossover , every week . This scale develop G. Chouinard A. Ross-Chouinard ( 15 ) design rate three type extrapyramidal symptom : parkinsonian , dystonic dyskinetic . Although scale may apply non-drug-induced extrapyramidal symptom , sensitivity often assessed evaluation drug-induced extrapyramidal symptom . The dose piracetam placebo increase every week 2000 mg 8000 mg/day dependence change movement disorder . The dos neuroleptic medication change month research . The patient take piracetam placebo addition constant medication . It emphasize improvement TD symptom piracetam addition appear short period ( 3-7 day ) comparison medication use treatment TD . Moreover , efficacy piracetam prove study , clinician obtain new , effective , safe drug TD treatment rapid onset action . References 1 . Lohr JB . Oxygen radical neuropsychiatric illness . Some speculation . Arch Gen Psychiatry 1991 ; 48 ( 12 ) :1097-1106 . 2 . Gouliaev AH , Senning A. Piracetam structurally related nootropics . Brain Res Brain Res Rev 1994 ; 19 ( 2 ) :180-222 . 3 . Kabes J , Sikora J , Pisvejc J , et al . Effect piracetam extrapyramidal side effect induce neuroleptic drug . Int Pharmacopsychiatry 1982 ; 17 ( 3 ) :185-92 . 4 . Giurgea C , Salama M. Nootropic Drugs . Prog Neuropsychopharmacol 1977 ; 1:235-247 . 5 . Pepeu G , Spignoli G. Nootropic drug brain cholinergic mechanism . Prog Neuropsychopharmacol Biol Psychiatry 1989 ; 13 ( Suppl ) : S77-88 . 6 . Pilch H , Muller WE . Piracetam elevate muscarinic cholinergic receptor density frontal cortex age young mouse . Psychopharmacology 1988 ; 94 ( 1 ) :74-8 . 7 . Tacconi M , Wurtman R. Piracetam : physiological disposition amd mechanism action . In : Fahn S , editor . Advances Neurology . NY : Raven Press ; 1986 . 8 . Sikora J , Kabes J , Pisvejc J . [ Management neuroleptic side-effects piracetam ( author 's transl ) ] . Cesk Psychiatr 1981 ; 77 ( 2 ) :137-42 . 9 . Kabes J , Sikora J , Stary O , et al . [ Effectiveness piracetam tardive dyskinesia - double-blind cross-over control trial placebo ] . Cesk Psychiatr 1983 ; 79 ( 5 ) :339-45 . 10 . Chaturvedi SK . Piracetam drug-induced dyskinesia . J Clin Psychiatry 1987 ; 48 ( 6 ) :255 . 11 . Obeso JA , Artieda J , Quinn N , et al . Piracetam treatment different type myoclonus . Clin Neuropharmacol 1988 ; 11 ( 6 ) :529-36 . 12 . Piperidou C , Maltezos E , Kafalis G , et al . Piracetam choreoathetosis . Lancet 1988 ; 2 ( 8616 ) :906 . 13 . Fleischhacker WW , Roth SD , Kane JM . The pharmacologic treatment neuroleptic-induced akathisia . J Clin Psychopharmacol 1990 ; 10 ( 1 ) :12-21 . 14 . Fehr C , Dahmen N , Klawe C , et al . Piracetam treatment tardive dyskinesia akathisia : case report . J Clin Psychopharmacol 2001 ; 21 ( 2 ) :248-9 . 15 . Chouinard G , Ross-Chouinard A , Annable L , Jones B. Extrapyramidal Symptom Rating Scale . Can J Neurol Sci ( abstract ) 1980 ; 7:233 .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>age 1875 DSMIV diagnosis tardive dyskinesia stable psychotropic regimen month prior entry duration TD least one year hospitalization Center family history Huntington 's disease drug alcohol abuse concurrent medial illness neurological disorder may contribute diagnosis TD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>tardive dyskinesia</keyword>
	<keyword>piracetam</keyword>
</DOC>